S&P lowers Meta's credit outlook to negative over AI spending

Published Friday, October 30, 2026 · 7:17 PM EDT

S&P Global Ratings lowered the outlook on Meta Platforms' AA- credit rating to negative on Friday, citing pressure on its balance sheet from elevated spending tied to artificial intelligence. The action changes the outlook on the rating, rather than the AA- rating itself.

Sources

Bloomberg Technology

In this story

Amazon sets up supplier financing to borrow as much as $80 billion

Amazon has established supplier financing arrangements to borrow as much as $80 billion against the value of hardware it buys, Bloomberg reported.

AI Infrastructure

Five technology giants commit more than $3T to future spending

Alphabet, Meta, Microsoft, Amazon and Oracle have committed more than $3T to future spending on data centres, leases, equipment and energy, The Next Web reported, citing Bloomberg. Alphabet accounts for more than $1T and Meta for more than $800B.

Products AI

Salesforce's Rune acquisition agreement reportedly worth $375 million

Salesforce's agreement to acquire military logistics software developer Rune Technologies is worth $375 million in cash and stock, Resilience Media reported. Rune builds AI software that helps the US military predict supply needs and manage logistics in the field.

Security Infrastructure

Linux flaw enables remote root exploit on servers using Multipath TCP

Anthropic researchers demonstrated remote root command execution through CVE-2026-98432 on a Linux server running a Multipath TCP listener, BleepingComputer reported.

Science

Researchers demonstrate faster water transport with more selective membrane

University of Queensland researchers demonstrated a membrane that increased water transport by approximately 44% and reduced ethanol transport by 90% in ethanol-water separation experiments, Phys.org reported.

AI Science

Insilico says AI-discovered Rentosertib has entered Phase III trials

Insilico Medicine says Rentosertib, its generative AI-discovered drug candidate also known as ISM001-055, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The company described the clinical advance in an announcement carried by News-Medical.Net.